Indivior Reports Third Quarter 2026 Financial Results

Q3'26 Total Net Revenue of $ 356 Million, Up 13% YoY Record Quarterly Total SUBLOCADE® Net Revenue of $ 267 Million in Q3'26, Up 22% YoY Record Quarterly Net Income of $ 137 Million and Record Non-GAAP Net Income of $ 161 Million in Q3'26 Record Quarterly Adjusted EBITDA of $ 211 Million in Q3'26, Up 76% YoY Net Income Margin of 39%, up 2,500 basis points YoY, Adjusted EBITDA Margin of 59% , Up 2,100 Basis Points YoY On Track to Close Merger with Supernus on November 2nd RICHMOND, Va., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today reported its financial results for the third quarter ended September 30, 2026.

GlobeNewsWire • 16 hours ago

Indivior Pharmaceuticals Inc. (INDV) Beats Q3 Earnings and Revenue Estimates

Indivior Pharmaceuticals Inc. (INDV) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $0.72 per share a year ago.

Zacks Investment Research • 14 hours ago

Indivior to Report Third Quarter 2026 Financial Results

RICHMOND, Va., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its third quarter 2026 financial results on Thursday, October 29, 2026. The results will be released at 7:00 a.m. U.S. EDT and will be available on the Company's website at www.indivior.com.

GlobeNewsWire • Oct 19, 2026

Indivior: Sublocade Growth And Improving Profitability Create Upside Potential

Indivior Pharmaceuticals is rated a buy, driven by strong SUBLOCADE sales, rising profitability, and an attractive valuation. Q2 2026 saw revenue up 14% and adjusted EBITDA up 111%, with SUBLOCADE revenue growing 21% year-over-year. INDV raised its 2026 guidance, now expecting $1.33B revenue and $720M adjusted EBITDA, with a 54% margin.

Seeking Alpha • Oct 14, 2026

Here's Why Indivior Pharmaceuticals Inc. (INDV) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Sep 24, 2026

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN) to Indivior Pharmaceuticals, Inc. (Nasdaq: INDV). Under the terms of the proposed transaction, shareholders of Supernus will receive 1.5401 common shares of Indivior for each share of Supernus that they own. KSF is seeking to determine whether this cons.

Business Wire • Sep 24, 2026

Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend

RICHMOND, Va., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) (“Indivior”) today announced that its Board of Directors declared a special cash dividend (the "Special Dividend") in the amount of (i) $8.13 per share of Indivior common stock payable to holders of record of the issued and outstanding Indivior common stock as of October 30, 2026 (the “Special Dividend Record Date”) (such holders, the “Special Dividend Record Holders”) and (ii) $8.13 per share of Indivior common stock underlying Indivior equity awards on the Special Dividend Record Date payable, upon vesting of such equity awards, to the holders of certain Indivior equity awards outstanding as of the Special Dividend Record Date (the “Special Dividend Award Holders”).

GlobeNewsWire • Sep 17, 2026

5 Small Drug Stocks Poised to Benefit From a Biotech Recovery

INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.

Zacks Investment Research • Sep 14, 2026

Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?

Indivior Pharmaceuticals Inc. (INDV) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Sep 2, 2026

Indivior Pharmaceuticals Inc. (INDV) Loses 12.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Indivior Pharmaceuticals Inc. (INDV) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Investment Research • Aug 31, 2026